Cambrian Bio Appoints Health Policy Veteran Adrienne Hallett as Vice President of Global Policy and Strategic Initiatives
NEW YORK, March 20, 2023 /PRNewswire/ -- Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, today announces the appointment of Adrienne Hallett as Vice President of Global Policy and Strategic Initiatives. In this new role, Hallett will be working with foundations, government institutions and other groups for investment into Cambrian Bio's pipeline and gaining approval to launch primary prevention trials.
- Hallett has over 25 years of health policy experience at the highest levels of the US government.
- She has drafted dozens of US health laws, including portions of the Affordable Care Act relating to prevention policies and programs.
- Hallett will engage across Cambrian Bio's operations and companies to envision and implement product-specific strategies designed to increase the availability of Cambrian Bio's products worldwide.
- Cambrian Bio recently unveiled two new pipeline companies: Isterian Biotech and Amplifier Therapeutics , with more announcements to come later in 2023.